Fibrates
On this page
Direct answer
Fibrates (gemfibrozil, fenofibrate, bezafibrate) are PPAR-alpha agonists that lower serum triglycerides by 30–50 per cent and raise HDL cholesterol by 10–15 per cent through increased lipoprotein lipase activity and fatty acid oxidation; they are first-line drug therapy when triglycerides exceed about 500 mg/dL to prevent pancreatitis, and add-on therapy in mixed dyslipidaemias. Fenofibrate is the fibrate compatible with statins (gemfibrozil markedly raises statin myopathy risk), and class adverse effects are cholelithiasis, myopathy and a reversible creatinine rise.
What you must remember
- Mechanism: PPAR-alpha activation induces lipoprotein lipase and apolipoprotein A1/A2 synthesis — triglyceride-rich particles clear faster and HDL rises.
- The pancreatitis-prevention indication: triglycerides persistently above 500 mg/dL despite diet, alcohol restriction and glycaemic control.
- Gemfibrozil 600 mg twice daily must not be combined with statins — it blocks statin glucuronidation and raises myopathy risk several-fold; fenofibrate 145–200 mg once daily is the safe partner.
- Cholelithiasis risk rises because biliary cholesterol secretion increases — a history of gallstones deserves caution.
- Fenofibrate raises serum creatinine reversibly without true glomerular injury; reduce dose in renal impairment and expect the creatinine to settle after withdrawal.
- Fenofibrate also lowers uric acid by about 20 per cent (renal uricosuria) — useful in the metabolic-syndrome patient with gout.
- Outcome benefit is strongest in the subgroup with high triglycerides and low HDL; fibrates are not substitutes for statins in LDL-driven risk.
- Class adverse effects: dyspepsia, myopathy (alone or with statins), cholelithiasis, and photosensitivity with fenofibrate.
How to work through a triglyceride problem
A 46-year-old executive with central obesity, type 2 diabetes on metformin, and alcohol intake of six units weekly has fasting triglycerides of 680 mg/dL, HDL 32, LDL 110, and normal amylase. The sequence matters more than the drug. First, remove the secondary drivers for four to six weeks: alcohol abstinence, glycaemic control review, and a check of oestrogen, antipsychotic or protease inhibitor exposure — these alone often return triglycerides to safe territory. Second, if triglycerides stay above 500 mg/dL, start fenofibrate 145 mg once daily, because the immediate threat is acute pancreatitis, not atherosclerosis; the fibrate class is the fastest triglyceride-lowering drug available. Third, address the LDL once triglycerides fall below 500 — statins, not fibrates, carry the mortality evidence, and a moderate-intensity statin now also helps the residual triglyceride. Fourth, add omega-3 fatty acid formulations if targets are missed. Fifth, check creatinine at six weeks and interpret it correctly — a 15–20 per cent rise on fenofibrate is pharmacological, not nephrotoxic, but it mandates dose review as the estimated glomerular filtration rate falls. This pathway explains why fibrates are niche drugs: powerful in their indication, inferior outside it.
Where students slip
The most penalised answer is gemfibrozil plus statin for mixed dyslipidaemia — the exam expects fenofibrate whenever a fibrate must accompany a statin, precisely because gemfibrozil inhibits statin clearance (CYP2C8-mediated glucuronidation) and produces myopathy. The second slip is assigning fibrates first-line status in ordinary high-LDL risk — they reduce coronary events mainly in the high-triglyceride/low-HDL phenotype, and statins remain the primary agents. The third is forgetting the creatinine story: a stem showing rising creatinine on fenofibrate with stable cystatin C or stable function expects the answer "reversible pharmacological effect, do not panic-discontinue" in stable patients, while acknowledging dose reduction in genuine renal impairment. The uric acid lowering by fenofibrate is the final viva pearl.
Frequently asked questions
At what triglyceride level do fibrates become first-line?
Above 500 mg/dL despite lifestyle measures, because pancreatitis risk drives the decision; below that threshold statins remain first-line for cardiovascular risk whatever the triglyceride value.
Why is fenofibrate the fibrate of choice with a statin?
Gemfibrozil inhibits the glucuronidation and CYP2C8-mediated clearance of statins, raising levels several-fold; fenofibrate lacks this interaction, making combination therapy acceptable with monitoring.
How does fenofibrate affect creatinine and renal function?
It reversibly raises serum creatinine by reducing its tubular secretion without lowering true glomerular filtration; the change resolves on stopping and dictates dose reduction in chronic kidney disease.
Do fibrates cause gallstones?
Yes — increased biliary cholesterol secretion increases lithogenicity and cholelithiasis risk, so a gallstone history is a relative contraindication.
Which dyslipidaemia phenotype benefits most from fibrate therapy?
High triglycerides with low HDL (the atherogenic dyslipidaemia of metabolic syndrome and diabetes), where subgroup analyses of fibrate trials show the clearest coronary event reduction.